Skip to main content

Table 1 Sample size scenarios

From: A phase IV randomised, open-label pilot study to evaluate switching from protease-inhibitor based regimen to Bictegravir/Emtricitabine/Tenofovir Alafenamide single tablet regimen in Integrase inhibitor-naïve, virologically suppressed HIV-1 infected adults harbouring drug resistance mutations (PIBIK study): study protocol for a randomised trial

Confidence level Lower limit of CI Upper limit of CI Sample size per arm Total sample size
95% 80 96% 62 124
90% 80 96% 50 100
80% 80 95% 38 76